Who Paid My Doc
Chalak Berzingi
Interventional Cardiology Roanoke, VA Medical Doctor
NPI 1225073711 CMS profile 512068
2001 Crystal Spring Ave Sw Ste 203, Roanoke, VA 24014
General payments
$14,084
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$10,220
Through program year 2025, Chalak Berzingi of Roanoke, VA is reported in the CMS Open Payments database as having received $14,084 across 112 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $10,220 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 67th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,512 | 23 | |
| 2024 | General | $1,382 | 13 | |
| 2023 | General | $367 | 5 | |
| 2022 | General | $3,321 | 19 | |
| 2021 | General | $180 | 4 | |
| 2020 | General | $268 | 10 | |
| 2019 | General | $6,054 | 38 |
Beside peers
- Chalak Berzingi
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to Chalak Berzingi were reported at $2,512. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | Chalak Berzingi | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $6,054 | $1,097 | $329–$3,048 | $163 |
| 2020 | $268 | $473 | $161–$1,480 | $114 |
| 2021 | $180 | $677 | $233–$1,827 | $132 |
| 2022 | $3,321 | $978 | $333–$2,724 | $149 |
| 2023 | $367 | $1,136 | $382–$2,986 | $160 |
| 2024 | $1,382 | $1,181 | $395–$3,326 | $164 |
| 2025 | $2,512 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 27 drugsPart D claims
1,896
Drug cost
$166,825
Branded share of claims
27.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 58 | $71,894 | |
| Jardiance Empagliflozin | Brand | 47 | $43,461 | |
| Entresto Sacubitril/Valsartan | Brand | 17 | $21,219 | |
| Repatha Sureclick Evolocumab | Brand | 11 | $8,276 | |
| Brilinta Ticagrelor | Brand | 15 | $6,458 | |
| Isosorbide Mononitrate Er Isosorbide Mononitrate | Brand | 177 | $1,855 | |
| Atorvastatin Calcium | Generic | 208 | $1,673 | |
| Ezetimibe | Generic | 58 | $1,466 | |
| Diltiazem 24hr Er (Cd) Diltiazem Hcl | Brand | 40 | $1,424 | |
| Metoprolol Succinate | Generic | 142 | $1,227 |
The 10 drugs with the highest cost, of 27 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 45 billing codesPaid by Medicare
$99,848
Medicare patients
322
Services billed
1,090
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 75% | |
| Arthritis | 51% | |
| Heart failure | 48% | |
| Diabetes | 46% | |
| Chronic kidney disease | 39% | |
| Atrial fibrillation | 30% | |
| COPD | 27% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
112 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Cardiology in Virginia
Deepak Talreja
Interventional Cardiology · Virginia Beach, VA
Rajiv Tayal
Interventional Cardiology · Fredericksburg, VA
Gansevoort Dunnington
Interventional Cardiology · Richmond, VA
Matthew Summers
Interventional Cardiology · Norfolk, VA
Noah Jones
Interventional Cardiology · Falls Church, VA
Michael Gen
Interventional Cardiology · Virginia Beach, VA
Related records
Interventional Cardiology in Virginia
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Virginia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.